292 related articles for article (PubMed ID: 28551662)
1. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
[TBL] [Abstract][Full Text] [Related]
2. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
4. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
5. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
[TBL] [Abstract][Full Text] [Related]
6. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
7. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience.
Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Yoshimitsu K
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1023-9. PubMed ID: 23238851
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents.
Chen S; Yu W; Zhang K; Liu W; Chen Q
Medicine (Baltimore); 2018 May; 97(21):e10832. PubMed ID: 29794774
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
11. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome.
Miyayama S; Matsui O
J Vasc Interv Radiol; 2016 Sep; 27(9):1269-1278. PubMed ID: 27345337
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
14. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of transcatheter arterial chemoembolization with 2-day-soluble gelatin sponge particles for hepatocellular carcinoma-comparison with insoluble gelatin sponge particles.
Kawai N; Sato M; Minamiguchi H; Ikoma A; Sanda H; Nakata K; Sato H; Sakaguchi H; Nakai M; Sonomura T
J Vasc Interv Radiol; 2013 Sep; 24(9):1383-90. PubMed ID: 23727419
[TBL] [Abstract][Full Text] [Related]
17. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
Iwazawa J; Hashimoto N; Ohue S; Mitani T
Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt.
Kang JW; Kim JH; Ko GY; Gwon DI; Yoon HK; Sung KB
Acta Radiol; 2012 Jun; 53(5):545-50. PubMed ID: 22547388
[TBL] [Abstract][Full Text] [Related]
20. Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations.
Matsumoto T; Endo J; Hashida K; Ichikawa H; Kojima S; Takashimizu S; Watanabe N; Yamagami T; Hasebe T
Minim Invasive Ther Allied Technol; 2015 Apr; 24(2):94-100. PubMed ID: 25263680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]